← Back to Search

Hormone Therapy

Angiotensin II + Compound 21 for Preeclampsia

Q: To whom does eligibility for this experiment extend?

Candidates must possess preeclampsia prophylaxis and fall in the age range of 18 to 45 if they wish to be accepted into this study. The total number of participants that the clinical trial is currently seeking is 30 individuals.

Q: Are applications for this experiment presently being accepted?

According to clinicaltrials.gov, this medical study is actively recruiting participants. The trial was first advertised on December 1st 2023 and its latest update occurred 4 days ago.

Q: What is the maximum capacity of participants for this trial?

Affirmative. As per information featured on clinicaltrials.gov, this clinical trial is presently enrolling participants. The development of the study was launched on December 1st 2023 and most recently modified on December 4th 2023; with 30 patients being sought from a single site location.

Q: Does this trial have an age restriction, and if so, what is it?

According to the eligibility requirements, this trial is open for individuals aged 18-45. However, there are 10 trials specifically designed for minors and 48 specialized studies targeting participants over 65 years of age.

Phase < 1

Recruiting

Research Sponsored by Anna Stanhewicz, PhD

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

18-45 years old

Be between 18 and 65 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up at the study visit, an average of 4 hours

Awards & highlights

Study Summary

This trial will help us better understand the mechanisms of blood vessel damage in women who have had preeclampsia, and how we can treat this risk of cardiovascular disease.

Who is the study for?

This trial is for women aged 18-45 who are 12 weeks to 5 years postpartum. It's specifically for those who experienced preeclampsia and those who didn't, without a history of hypertension or metabolic disease before pregnancy, skin diseases, tobacco use, or current pregnancy.Check my eligibility

What is being tested?

The study investigates the balance of angiotensin II receptors in blood vessels after preeclampsia using intradermal microdialysis. Angiotensin II and Compound 21 are being tested to understand their effects on restoring microvascular function.See study design

What are the potential side effects?

Potential side effects may include local reactions at the site where drugs are delivered into the skin such as redness, swelling or itching due to Angiotensin II or Compound 21. Allergic reactions could also occur.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am between 18 and 45 years old.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ at the study visit, an average of 4 hours

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~at the study visit, an average of 4 hours

This trial's timeline: 3 weeks for screening, Varies for treatment, and at the study visit, an average of 4 hours for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Change in microvascular ang II-mediated constriction response measured by laser-Doppler flowmetry

Change in microvascular angiotensin II (ang II) type 2 receptor (AT2R)-mediated dilation response measured by laser-Doppler flowmetry

Trial Design

2Treatment groups

Experimental Treatment

Group I: History of a preeclampsiaExperimental Treatment2 Interventions

Women who had preeclampsia in their most recent pregnancy

Group II: History of a healthy pregnancyExperimental Treatment2 Interventions

Women who had an uncomplicated pregnancy

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Angiotensin II

2010

Completed Phase 4

~260

0 / 1Eligibility criteria met

Find a Location

Who is running the clinical trial?

Anna Stanhewicz, PhDLead Sponsor

9 Previous Clinical Trials

350 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

To whom does eligibility for this experiment extend?

"Candidates must possess preeclampsia prophylaxis and fall in the age range of 18 to 45 if they wish to be accepted into this study. The total number of participants that the clinical trial is currently seeking is 30 individuals."

Answered by AI

Are applications for this experiment presently being accepted?

"According to clinicaltrials.gov, this medical study is actively recruiting participants. The trial was first advertised on December 1st 2023 and its latest update occurred 4 days ago."

Answered by AI

What is the maximum capacity of participants for this trial?

"Affirmative. As per information featured on clinicaltrials.gov, this clinical trial is presently enrolling participants. The development of the study was launched on December 1st 2023 and most recently modified on December 4th 2023; with 30 patients being sought from a single site location."

Answered by AI

Does this trial have an age restriction, and if so, what is it?

"According to the eligibility requirements, this trial is open for individuals aged 18-45. However, there are 10 trials specifically designed for minors and 48 specialized studies targeting participants over 65 years of age."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Balance of Angiotensin II Receptors in Vessel Function After Preeclampsia

Anna Stanhewicz, PhD 2023. "Balance of Angiotensin II Receptors in Vessel Function After Preeclampsia". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06157580.

All > Preeclampsia